Conclusions

In patients with IPF, the effect of nintedanib in reducing the rate of decline in FVC was similar irrespective of TORVAN stage at baseline.
The adverse event profile of nintedanib was consistent across subgroups by TORVAN stage. In both the nintedanib and placebo groups, adverse events leading to treatment discontinuation were more frequent in patients at TORVAN stages II to IV than stage I, while the proportion of patients with serious adverse events increased with TORVAN stage.